Medical/Pharmaceuticals
Daewoong, first-in-class PRS-inhibitor for Idiopathic Pulmonary Fibrosis(IPF) shows promising result in early stage clinical test
* We confirmed the safety of 'DWN12088' and secured grounds for establishing treatment dosage * Confirming the potential as a treatment for IPF and planning to apply for Ph.2 within 2021 * 2nd ODD granted as treatment for systemic sclerosis from the US FDA SEOUL, South Korea, May 27, 2021...
2021-05-27 21:00
1917
Menarini Silicon Biosystems launches new breakthrough DEPArray™ PLUS image-based cell sorter to isolate rare cells with single cell precision
DEPArray™ PLUS – the new automated and versatile platform to investigate pre-selected rare cell populations from various samples with 100% purity, now enhanced with 9 fluorescent channels and remarkably improved user experience BOLOGNA, Italy and HUNTINGDON VALLEY, Pa., May 27, 2021 /PRNewswire/ ...
2021-05-27 15:00
1705
Foresee Pharmaceuticals Announces FDA Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer; Accord BioPharma to Head the U.S. Commercialization
TAIPEI, May 26, 2021 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for CAMCEVI® 42 mg, a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate, as a ...
2021-05-27 11:33
2962
TransThera announces collaboration with Roche to evaluate TT-00420 as part of a novel combination to treat GI cancers in China
NANJING, China, May 26, 2021 /PRNewswire/ -- TransThera Biosciences Co. Ltd. ( "TransThera" ), a clinical stage biotechnology company dedicated to developing innovative therapeutics across oncology, cardiovascular, and inflammatory diseases with major unmet medical needs globally and inChina, to...
2021-05-26 21:00
1813
Gracell Biotechnologies Hosting Key Opinion Leader Webinar on High Risk Multiple Myeloma, Treatment Challenges and Dual-Targeting CAR-T with Overnight Manufacturing - a Novel Approach for Treatment of Multiple Myeloma
SUZHOU, China and PALO ALTO, Calif., May 26, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-05-26 21:00
10766
IT Tech Packaging, Inc. Officially Obtains FDA Approval for Surgical Mask Products
BAODING, China, May 26, 2021 /PRNewswire/ -- IT Tech Packaging, Inc. (NYSE AMERICAN: ITP) ("IT Tech Packaging" or the "Company"), a leading manufacturer and distributor of diversified paper products inNorth China, today announced that the Company has officially obtained approval for surgical mask...
2021-05-26 20:00
14990
Prosit Sole Biotechnology Initiates First-In-Human Clinical Trial of Novel Interferon Lambda Chimera in US
BALTIMORE, May 26, 2021 /PRNewswire/ -- Prosit Sole Biotechnology, a clinical-stage biotech company developing novel protein therapeutics, today announces that it has initiated the first-in-human ("FIH") Phase I clinical trial of PSP001 in US. PSP001 is a novel, long acting and potent interferon ...
2021-05-26 16:10
1356
I Peace's cell manufacturing facility "Peace Engine Kyoto" receives third-party certification as US cGMP compliant: the facility now meets the standard for both the US and Japanese markets
PALO ALTO, Calif., May 25, 2021 /PRNewswire/ -- I Peace, Inc. (CEO: Koji Tanabe ), aPalo Alto-based biotech start-up focusing on Nobel Prize-winning technology "induced pluripotent stem cells (iPSCs)" received a third-party certification as US FDA cGMP compliant for its manufacturing facility "Pea...
2021-05-26 03:00
1794
Procyrion Announces Successful First-in-Human Cases in Cardiorenal Syndrome (CRS) Patients with Aortix™ Percutaneous Mechanical Circulatory Support Device
Pilot CRS Study to Evaluate Performance of Novel Aortix device in Australia and the U.S. HOUSTON, May 25, 2021 /PRNewswire/ -- Procyrion, Inc., a medical device company dedicated to improving outcomes for patients with cardiac and renal impairment, announced today successful treatment of the fir...
2021-05-25 19:02
1231
Concord Medical Receives Notification from NYSE Regarding Delayed Filing of 2020 Annual Report
BEIJING, May 25, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone r...
2021-05-25 18:02
6391
Singapore-based HeMo Bioengineering Receives China's NMPA Approval for flagship Afentta(TM) Aspiration Catheter
SINGAPORE, May 24, 2021 /PRNewswire/ -- HeMo Bioengineering Ltd ("HeMo"), a Singapore-based medical device company with a focus on treating stroke patients, is pleased to announce that its Afentta™ intracranial thrombectomy aspiration catheter – a product developed byHeMo's branch in China – has ...
2021-05-24 20:01
2229
Two Products of Zhaoke Ophthalmology (6622.HK) Passed The On-Site Inspection for Drug Registration of The National Medical Products Administration and The GMP Compliance Inspection of The Guangdong Medical Products Administration
HONG KONG, May 24, 2021 /PRNewswire/ -- Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company"; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs, announc...
2021-05-24 16:58
5649
Genesis MedTech Group Raises Significant Growth Investment in Latest Round of Series B Financing
SINGAPORE, May 23, 2021 /PRNewswire/ -- Genesis MedTech Group ("Genesis"), a leading medical device company, today announced it has completed its Series B round, raising significant growth financing. General Atlantic, a leading global growth equity firm, led the funding with participation from CI...
2021-05-24 11:08
2958
A 'Game Changer' COVID-19 drug from Korea was introduced in a world class academic journal
SEOUL South Korea, May 23, 2021 /PRNewswire/ -- Hyundai Bioscience (KOSDAQ 048410) announced on the 24th that CNPharm, its major shareholding bio tech company, published an article containing the research results of CP-COV03, a Niclosamide-based oral treatment for COVID-19 based on its proprietar...
2021-05-24 08:16
2571
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna's COVID-19 Vaccine
CAMBRIDGE, Mass. and INCHEON, South Korea, May 22, 2021 /PRNewswire/ -- Moderna (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Samsung Biologics (KRX: 207940.KS), a leading global CDMO providing a fully integrated end-to-end contract develop...
2021-05-23 00:00
9692
Concord Medical Announces Changes in Board of Directors
BEIJING, May 21, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone r...
2021-05-22 04:15
10897
CUREXO's spinal surgery robot, 'CUVIS-spine' acquired FDA (US) licensing.
* 'CUVIS-spine' is available in all countries by acquiring the license from the FDA (US), Korea andEurope. * 'CUVIS-spine' reduces surgery duration with Minimally Invasive Surgery (MIS). SEOUL, South Korea, May 21, 2021 /PRNewswire/ -- On the 20th, the Medical robot specialist company CUREX...
2021-05-22 03:52
3714
Kintor Announced (1) FDA Has Greenlighted Proxalutamide's Phase III Study for Hospitalized Male and Female COVID-19 Patients to Be Conducted; and (2) Inclusion of Female Outpatients in Proxalutamide's Phase III Study for Mild to Moderate COVID-19
SUZHOU, China, May 19, 2021 /PRNewswire/ -- On May 18, Kintor Pharmaceutical Limited (HKEX.9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the U.S. Food and Drug Administration (FDA) has greenlighted proxalutamide's ph...
2021-05-20 09:47
9482
Duality Biologics Completed $90 Million Series B Financing
PRINCETON, N.J. and SHANGHAI and SUZHOU, China, May 19, 2021 /PRNewswire/ -- Duality Biologics (DualityBio or Company), an innovative biotech company, announced the completion of$90 million series B financing today. This round of financing was led by Lilly Asia Ventures (LAV) and jointly invested...
2021-05-20 08:00
2015
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
* Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages * Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has...
2021-05-20 06:00
8654
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Vizzio Technologies Strengthens Leadership As Global Growth Accelerates
[Picked up by 294 media titles]
2026-02-11 14:59
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 270 media titles]
2026-02-17 19:12
Most Read
Datasea Reports Second Fiscal Quarter 2026 Results
2026-02-12 22:20
6977
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
6737
NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell
2026-02-12 21:56
6034
